These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

645 related articles for article (PubMed ID: 27062356)

  • 1. Outcomes of Radioembolization in the Treatment of Hepatocellular Carcinoma with Portal Vein Invasion: Resin versus Glass Microspheres.
    Biederman DM; Titano JJ; Tabori NE; Pierobon ES; Alshebeeb K; Schwartz M; Facciuto ME; Gunasekaran G; Florman S; Fischman AM; Patel RS; Nowakowski FS; Kim E
    J Vasc Interv Radiol; 2016 Jun; 27(6):812-821.e2. PubMed ID: 27062356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Open-label prospective study of the safety and efficacy of glass-based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis.
    Kokabi N; Camacho JC; Xing M; El-Rayes BF; Spivey JR; Knechtle SJ; Kim HS
    Cancer; 2015 Jul; 121(13):2164-74. PubMed ID: 25847227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.
    Kokabi N; Galt JR; Xing M; Camacho JC; Barron BJ; Schuster DM; Kim HS
    J Vasc Interv Radiol; 2014 Feb; 25(2):277-87. PubMed ID: 24461133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Favorable survival time provided with radioembolization in hepatocellular carcinoma patients with and without portal vein thrombosis.
    Ozkan ZG; Poyanli A; Ucar A; Kuyumcu S; Akyuz F; Keskin S; Saglam S; Yilmaz E; Karaca C; Turkmen C
    Cancer Biother Radiopharm; 2015 Apr; 30(3):132-8. PubMed ID: 25760644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of yttrium-90 microspheres in patients with advanced hepatocellular carcinoma and portal vein thrombosis.
    Tsai AL; Burke CT; Kennedy AS; Moore DT; Mauro MA; Dixon RD; Stavas JM; Bernard SA; Khandani AH; O'Neil BH
    J Vasc Interv Radiol; 2010 Sep; 21(9):1377-84. PubMed ID: 20691606
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Abouchaleh N; Gabr A; Ali R; Al Asadi A; Mora RA; Kallini JR; Mouli S; Riaz A; Lewandowski RJ; Salem R
    J Nucl Med; 2018 Jul; 59(7):1042-1048. PubMed ID: 29217739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis.
    Iñarrairaegui M; Thurston KG; Bilbao JI; D'Avola D; Rodriguez M; Arbizu J; Martinez-Cuesta A; Sangro B
    J Vasc Interv Radiol; 2010 Aug; 21(8):1205-12. PubMed ID: 20598574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Yttrium-90 Glass-Based Microsphere Radioembolization in the Treatment of Hepatocellular Carcinoma Secondary to the Hepatitis B Virus: Safety, Efficacy, and Survival.
    Biederman DM; Titano JJ; Lee KM; Pierobon ES; Schwartz M; Facciuto ME; Gunasekaran G; Florman S; Fischman AM; Patel RS; Tabori NE; Nowakowski FS; Kim E
    J Vasc Interv Radiol; 2015 Nov; 26(11):1630-8. PubMed ID: 26321014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis.
    Kulik LM; Carr BI; Mulcahy MF; Lewandowski RJ; Atassi B; Ryu RK; Sato KT; Benson A; Nemcek AA; Gates VL; Abecassis M; Omary RA; Salem R
    Hepatology; 2008 Jan; 47(1):71-81. PubMed ID: 18027884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of Yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis.
    Salem R; Lewandowski R; Roberts C; Goin J; Thurston K; Abouljoud M; Courtney A
    J Vasc Interv Radiol; 2004 Apr; 15(4):335-45. PubMed ID: 15064336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular Carcinoma.
    Allimant C; Kafrouni M; Delicque J; Ilonca D; Cassinotto C; Assenat E; Ursic-Bedoya J; Pageaux GP; Mariano-Goulart D; Aho S; Guiu B
    J Vasc Interv Radiol; 2018 Dec; 29(12):1662-1670.e4. PubMed ID: 30217745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis.
    Garin E; Rolland Y; Edeline J; Icard N; Lenoir L; Laffont S; Mesbah H; Breton M; Sulpice L; Boudjema K; Rohou T; Raoul JL; Clement B; Boucher E
    J Nucl Med; 2015 Mar; 56(3):339-46. PubMed ID: 25678490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation.
    Sangro B; Carpanese L; Cianni R; Golfieri R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Van Buskirk M; Bilbao JI; Ettorre GM; Salvatori R; Giampalma E; Geatti O; Wilhelm K; Hoffmann RT; Izzo F; Iñarrairaegui M; Maini CL; Urigo C; Cappelli A; Vit A; Ahmadzadehfar H; Jakobs TF; Lastoria S;
    Hepatology; 2011 Sep; 54(3):868-78. PubMed ID: 21618574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Superselective yttrium-90 radioembolization for hepatocellular carcinoma yields high response rates with minimal toxicity.
    Padia SA; Kwan SW; Roudsari B; Monsky WL; Coveler A; Harris WP
    J Vasc Interv Radiol; 2014 Jul; 25(7):1067-73. PubMed ID: 24837982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resin Versus Glass Microspheres for
    Van Der Gucht A; Jreige M; Denys A; Blanc-Durand P; Boubaker A; Pomoni A; Mitsakis P; Silva-Monteiro M; Gnesin S; Lalonde MN; Duran R; Prior JO; Schaefer N
    J Nucl Med; 2017 Aug; 58(8):1334-1340. PubMed ID: 28082436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes.
    Salem R; Lewandowski RJ; Mulcahy MF; Riaz A; Ryu RK; Ibrahim S; Atassi B; Baker T; Gates V; Miller FH; Sato KT; Wang E; Gupta R; Benson AB; Newman SB; Omary RA; Abecassis M; Kulik L
    Gastroenterology; 2010 Jan; 138(1):52-64. PubMed ID: 19766639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Same-Day Yttrium-90 Radioembolization: Feasibility with Resin Microspheres.
    Li MD; Chu KF; DePietro A; Wu V; Wehrenberg-Klee E; Zurkiya O; Liu RW; Ganguli S
    J Vasc Interv Radiol; 2019 Mar; 30(3):314-319. PubMed ID: 30819470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intrahepatic Cholangiocarcinoma Treated with Transarterial Yttrium-90 Glass Microsphere Radioembolization: Results of a Single Institution Retrospective Study.
    Gangi A; Shah J; Hatfield N; Smith J; Sweeney J; Choi J; El-Haddad G; Biebel B; Parikh N; Arslan B; Hoffe SE; Frakes JM; Springett GM; Anaya DA; Malafa M; Chen DT; Chen Y; Kim RD; Shridhar R; Kis B
    J Vasc Interv Radiol; 2018 Aug; 29(8):1101-1108. PubMed ID: 30042074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective longitudinal quality of life and survival outcomes in patients with advanced infiltrative hepatocellular carcinoma and portal vein thrombosis treated with Yttrium-90 radioembolization.
    Xing M; Kokabi N; Camacho JC; Kim HS
    BMC Cancer; 2018 Jan; 18(1):75. PubMed ID: 29329568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radioembolization Is a Safe and Effective Treatment for Hepatocellular Carcinoma with Portal Vein Thrombosis: A Propensity Score Analysis.
    Cho YY; Lee M; Kim HC; Chung JW; Kim YH; Gwak GY; Bae SH; Kim do Y; Heo J; Kim YJ
    PLoS One; 2016; 11(5):e0154986. PubMed ID: 27149067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.